Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis

European Journal of Pharmacology

Volumn 389, Issue 2-3, 2000, Pages 201-207

  Heran, Christopher ^a   Morgan, Suzanne ^a   Kasiewski, Charles ^a   Bostwick, Jeffrey ^a   Bentley, Ross ^a   Klein, Scott ^a   Chu, Valeria ^a   Brown, Karen ^a   Colussi, Dennis ^a   Czekaj, Mark ^a   Perrone, Mark ^a   Leadley Jr , Robert ^a  

^a Cardiovascular Drug Discovery   (United States)

Author keywords

(In vivo); Antithrombotic; Coagulation factor Xa; Heparin; Thrombin

Indexed keywords

2 (3 CARBAMIMIDOYL BENZYL) 3 [(3',4'DIMETHOXY BIPHENYL 4 CARBONYL)AMINO] BUTYRIC ACID METHYL ESTER TRIFLUOROACETIC ACID; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; HEPARIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CAROTID ARTERY THROMBOSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FIBRIN FORMATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RAT; THROMBOCYTE ACTIVATION; THROMBOGENESIS;

AMIDINES; ANIMALS; BENZAMIDES; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACTOR XA; FIBRINOLYTIC AGENTS; HEPARIN; MALE; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034681376     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00902-4     Document Type: Article

References (28)

1. TIMI 9B Investigators , Antman E.M. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation. 90:1996;911-921.
2. Bush L.R. Argatroban, a selective, potent thrombin inhibitor. Cardiovasc. Drug Rev. 9:1992;247-263.
3. Callas K., Fareed J. Comparative pharmacology of site directed antithrombin agents. Implications in drug development. Thromb. Haemost. 74:1995;473-481.
4. Catella-Lawson F. Direct thrombin inhibitors in cardiovascular disease. Coron. Artery Dis. 8:1997;105-111.
5. Finkle C.D., St. Pierre A., Leblond L., Deschenes I., DiMaio J., Winocour P.D. BCH-2763, a novel potent parenteral thrombin inhibitor, is an effective antithrombotic agent in rodent models of arterial and venous thrombosiscomparisons with heparin, r-hirudin, hirulog, inogatran and argatroban. Thromb. Haemost. 79:1998;431-438.
6. Gold H.K., Torres F.W., Garabedian H.D., Werner W., Jang I.-K., Khan A., Hagstrom J.N., Yasuda T., Leinbach R.C., Newell J.B., Bovill E.G., Stump D.C., Collen D. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J. Am. Coll. Cardiol. 21:1993;1039-1047.
7. Hara T., Yokoyama A., Tanabe K., Ishihara H., Iwamoto M. DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb. Haemost. 74:1995;635-639.
8. Hemker H.C., Beguin S. Mode of action of heparin and related drugs. Semin. Thromb. Haemost. 14(Suppl. 1):1991;29-34.
9. Herbert J.M., Bernat A., Dol F., Herault J.P., Crepon B., Lormeau J.C. DX-9065A, a novel synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. J. Pharmacol. Exp. Ther. 276:1996;1030-1038.
10. Hirsh J., Levine M.N. Low molecular weight heparin. Blood. 79:1992;1-17.
11. MINT Investigators , Jang K.-K., Brown D.F.M., Giuglano R.P., Anderson H.V., Losordo D., Nicolau J.C., Dutra O.P., Bazzino O., Viamonte V.M., Norbady R., Liprandi A.S., Massey T.J., Dinsmore R., Schwarz R.P. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with Novastan and TPA (MINT) study. J. Am. Col. Cardiol. 33:1999;1879-1885.
12. Kawasaki T., Sato K., Sakai Y., Hirayama F., Koshio H., Taniuchi Y., Matsumoto Y. Comparative studies of an orally-active factor Xa inhibitor, YM-60828, with other antithrombotic agents in a rat model of arterial thrombosis. Thromb. Haemost. 79:1998;410-416.
13. Kurz K.D., Main B.W., Sandusky G.E. Rat model of arterial thrombosis induced by ferric chloride. Thromb. Res. 60:1990;269-280.
14. Mann K.G. The assembly of blood clotting complexes on membranes. TIBS. 12:1987;229-233.
15. Morishima Y., Tanabe K., Terada Y., Hara T., Kunitada S. Antithrombotic and hemorrhagic effects of DX9065a, a direct and selective factor Xa inhibitor: comparison with a direct thrombin inhibitor and antithrombin III-dependent anticoagulants. Thromb. Haemost. 78:1997;1366-1371.
16. National Research Council Guide for the Care and Use of Laboratory Animals. 1996;National Academy Press, Washington, DC.
17. Rosenberg R.D., Damus P.S. Purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. 248:1973;6498-6505.
18. Sato K., Kawasaki T., Hisamichi N., Taniuchi Y., Hirayama F., Koshio H., Matsumoto Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 123:1998;92-96.
19. Schumacher W.A., Heran C.L., Steinbacher T.E. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time. J. Cardiovasc. Pharmacol. 28:1996;19-25.
20. Schumacher W.A., Steinbacher T.E., Heran C.L., Seiler S.M., Michel I.M., Ogletree M.l. Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. J. Pharmacol. Exp. Ther. 267:1993;1237-1242.
21. Schwarz R.P. Jr., Becker J.C.-P., Brooks R.L., Hursting M.J., Joffrion J.L., Knappenberger G.D., Kogan R.P., Kogan P.W., McKinney A.A. The preclinical and clinical pharmacology of Novastan (argatroban): a small-molecule, direct thrombin inhibitor. Clin. Appl. Thrombosis/Hemostasis. 3:1997;1-15.
22. Smith G.F., Gifford-Moore D., Craft T.J., Chirgadze N., Ruterbories K.J., Lindstrom T.D., Satterwhite J.H. Efegatran: a new cardiovascular anticoagulant. Pifarre R. New Anticoagulants for the Cardiovascular Patient. 1997;265-300 Hanley & Belfus, Philadelphia, PA.
23. Taniuchi Y., Sakai Y., Hisamichi N., Kayama M., Mano Y., Sato K., Hirayama F., Koshio H., Matsumoto Y., Kawasaki T. Biochemical and pharmacological characterization of YM-60828, a newly synthesized and orally active inhibitor of human Factor Xa. Thromb. Haemost. 79:1998;543-548.
24. Tapparelli C., Metternich R., Ehrhardt C., Cook N.S. Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. TiPS. 14:1993;366-376.
25. GUSTO IIb Investigators , Topol E.J. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. 335:1996;775-782.
26. Theroux P., Perez-Villa F., Waters D., Lesperance J., Shabani F., Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation. 91:1995;2132-2139.
27. Theroux P., Waters D., Lam J., Juneau M., McCans J. Reactivation of unstable angina after the discontinuation of heparin. N. Engl. J. Med. 27:1992;766-773.
28. White H.D., Aylward P.E., Frey M.J., Adgey A.A.J., Nair R., Hillis W.S., Shalev Y., Brown M.A., French J.K., Collins R., Maraganore J., Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation. 96:1997;2155-2161.